Physician profile
Andrew C Phan
NPI 1710164736
$8,476.84
in general payments reported to CMS, 2019-2025
27 companies · $1,512 in 2025
The $1,512 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,088 · 2020: $815 · 2021: $1,208 · 2022: $1,273 · 2023: $803 · 2024: $1,778 · 2025: $1,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,993 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,993.02 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,789.21 | 2019-2025 | |
| Janssen Biotech, INC. | $1,511.11 | 2021-2025 | Tremfya |
| Amgen INC. | $1,214.79 | 2019-2025 | Krystexxa |
| Aurinia Pharma U.S., INC. | $538.00 | 2022-2025 | Lupkynis |
| Ucb, INC. | $447.89 | 2022-2024 | Cimzia |
| Pfizer INC. | $413.80 | 2019-2025 | |
| Radius Health, INC. | $346.10 | 2019-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $340.80 | 2019-2025 | |
| Celgene Corporation | $265.53 | 2019 | |
| Glaxosmithkline, LLC. | $209.32 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $188.25 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $166.99 | 2019-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $166.05 | 2024-2025 | Acthar |
| Lilly USA, LLC | $163.29 | 2019-2025 | Taltz, Zepbound, Olumiant |
| Genzyme Corporation | $140.16 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $104.01 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.01 | 2019-2025 | Ofev |
| Ani Pharmaceuticals, INC. | $81.47 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Kiniksa Pharmaceuticals International, Plc | $64.81 | 2024 | Arcalyst |
| Horizon Therapeutics Plc | $52.52 | 2019 | |
| Merck Sharp & Dohme LLC | $39.42 | 2019 | |
| Astellas Pharma US INC | $37.50 | 2019 | |
| Leo Pharma INC. | $29.39 | 2024 | Adbry |
| Sandoz INC. | $27.22 | 2024 | Hyrimoz |
| Genentech USA, INC. | $17.71 | 2023 | Actemra |
| Janssen Pharmaceuticals, INC | $16.87 | 2019 | |
| Sanofi Pasteur INC. | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.